Dr. Kai Tsao is the Medical Director of the Ruttenberg Treatment Center at the Tisch Cancer Institute at Mount Sinai Hospital. His mission in this position is to lead the multidisciplinary treatment center to provide the highest quality of patient-centered care for those affected by Cancer and blood disorders. 

He is an Associate Professor of Medicine, Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and is on staff at the Tisch Cancer Institute at Mount Sinai Hospital and the Mount Sinai Queens Infusion Center. 

Dr. Tsao is board certified in Internal Medicine, Hematology and Medical Oncology. He is actively involved in research on the development of new therapies in the treatment of genitourinary cancers. He has received several merit awards from the American Society of Clinical Oncology. His main objective is to define the clinical and molecular phenotype of prostate, kidney and bladder cancers, as well as new therapies in these disease states. He is principal investigator in several ongoing clinical trials and has authored more than 40 peer-reviewed publications. 

• Medical Director of the Ruttenberg Treatment Center of the Tisch Cancer Institute at Mount Sinai Hospital
• Principal investigator on several clinical trials 
• Participant in research on the development of new therapies for the treatment of genitourinary cancers
• Lecturer at the Icahn School of Medicine at The Mount Sinai School of Medicine
• Author of more than 40 scientific publications 
• Recipient of several merit awards given by the American Society of Clinical Oncology 
• Member of:
  
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Society of Hematology